StevenI.ShermanMD
Endocrinology • Houston, TXDiabetes, Lipid Metabolism, Thyroid
Professor of Medicine
Dr. Sherman is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1515 Holcombe Blvd
Houston, TX 77030Phone+1 713-792-6161Fax+1 713-745-7296
Education & Training
Johns Hopkins UniversityFellowship, Endocrinology, Diabetes, and Metabolism, 1988 - 1991- Johns Hopkins UniversityResidency, Internal Medicine, 1986 - 1988
- Johns Hopkins UniversityInternship, Internal Medicine, 1985 - 1986
- Johns Hopkins University School of MedicineClass of 1985
Certifications & Licensure
FL State Medical License 2021 - Present
NY State Medical License 1985 - Present
TN State Medical License 2023 - 2027
GA State Medical License 2023 - 2026
OK State Medical License 2020 - 2026
WA State Medical License 2023 - 2026
AL State Medical License 2023 - 2025
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Endocrinology, Diabetes and Metabolism
- Join now to see all
Awards, Honors, & Recognition
- America's Top Doctors Castle Connolly, 2009-2014
- Top Doctors:SE Texas Castle Connolly, 2013
- America's Top Doctors for Cancer Castle Connolly, 2005-2013
- Join now to see all
Clinical Trials
- Bortezomib in Treating Patients With Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy Start of enrollment: 2004 Dec 01
- Recombinant Thyrotropin PET-CT Fusion Scanning in Thyroid Cancer Start of enrollment: 2001 Mar 01
- Efficacy of XL184 (Cabozantinib) in Advanced Medullary Thyroid Cancer Start of enrollment: 2008 Jun 01
Publications & Presentations
PubMed
- Polygenic Score for Clinicopathologic Features and Survival Outcomes in Papillary Thyroid Carcinoma.Sophie Li, Guibin Zheng, Li Xu, Maitrayee Goswami, Mark E Zafereo
JAMA Otolaryngology-- Head & Neck Surgery. 2025-02-01 - 1 citationsEfficacy and Safety of Selective RET Inhibitors in Patients with Advanced Hereditary Medullary Thyroid Carcinoma.Sarah Hamidi, Sireesha Yedururi, Mimi I Hu, Naifa L Busaidy, Steven I Sherman
Thyroid. 2025-01-01 - Fusion-Positive Thyroid Carcinoma: From Diagnosis to Targeted Therapy.Vicente R Marczyk, Sasan Fazeli, Ramona Dadu, Naifa L Busaidy, Priyanka Iyer
JCO Precision Oncology. 2025-01-01
Journal Articles
- Targeted Therapy in Advanced Thyroid Cancer to Resensitize Tumors to Radioactive IodineThinh Vu, Naifa L Busaidy, Maria E Cabanillas, Steven G Waguespack, Steven I Sherman, Mark Zafereo, The Journal of Clinical Endocrinology and Metabolism
Lectures
- New Medical Options for the Treatment of Advanced Thyroid CancerENDO 2019 - New Orleans, LA - 3/24/2019
Other
- Chemotherapy and immunotherapy for medullary thyroid cancerSherman SI
http://www.uptodate.com/contents/chemotherapy-and-immunotherapy-for-medullary-thyroid-cancer
UpToDate, Wolters Kluwer Health - 2013-02-21 - Chemotherapy for differentiated thyroid cancerSherman SI
http://www.uptodate.com/contents/chemotherapy-for-differentiated-thyroid-cancer
UpToDate, Wolters Kluwer Health - 2013-02-25
Press Mentions
Preview of the 93rd American Thyroid Association Annual MeetingJuly 1st, 2024
Cabozantinib Improved Survival in Medullary Thyroid Cancer with RET MutationsOctober 23rd, 2015
Professional Memberships
- Member
- Member
- Member
- Member
- International Thyroid Oncology GroupMember
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
